Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies

Cancer Research

Volumn 66, Issue 24, 2006, Pages 11520-11539

  Horsman, Michael R ^a   Siemann, Dietmar W ^b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIMETHYL 5 (2 OXO 1H INDOL 3 YLMETHYLENE) 3 PYRROLEPROPIONIC ACID; 5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ANGINEX; ANGIOSTATIN; ARGININE DEIMINASE; ARSENIC TRIOXIDE; BEVACIZUMAB; COMBRETASTATIN A1 PHOSPHATE; COMBRETASTATIN A4 PHOSPHATE; ENDOSTATIN; FUMAGILLOL CHLOROACETYLCARBAMATE; MITOFLAXONE; MN 029; MONOCLONAL ANTIBODY DC101; N ACETYLCOLCHINOL PHOSPHATE; NPI 2358; SEMAXANIB; SERINE 2 METHOXY 5 [2 (3,4,5 TRIMETHOXYPHENYL)VINYL]ANILIDE; SU 11657; SU 5474; SUNITINIB; SURAMIN; THALIDOMIDE; THROMBOSPONDIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULAR TARGETING AGENT; VASCULOTROPIN ANTIBODY; VATALANIB; VINCA ALKALOID;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BLOOD FLOW; BLOOD OXYGENATION; BLOOD PH; CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RADIOTHERAPY; COMBINATION CHEMOTHERAPY; DRUG MECHANISM; DRUG TARGETING; HUMAN; HYPERTHERMIA; MULTIMODALITY CANCER THERAPY; NONHUMAN; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; REVIEW; TISSUE PRESSURE; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 33748869678     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-06-2848     Document Type: Review

References (261)

1. Brem S, Brem H, Folkman J, Finkelstein D, Patz A. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res 1976;36:2807-12.
2. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? Cancer Res 1986;46:467-73.
3. Hahnfeldt P, Panigrahy D, Folkman J, Hlatky L. Tumor development under angiogenic signaling: a dynamic theory of tumor growth, treatment response, and postvascular dormancy. Cancer Res 1999;59:4770-5.
4. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003;3:401-10.
5. Stoeltzing O, Ellis LM. The role of microvasculature in metastasis formation. In: Siemann DW, editor. Vascular-targeted therapies in oncology. Chichester: John Wiley & Sons, Ltd.; 2006. p.31-62.
6. Vaupel P, Kallinowski F, Okunieff P. Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989;49:6449-65.
7. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004;14:198-206.
8. Coley Nauts H, Fowler GA, Bogatko FH. A review of the influence of bacterial infection and bacterial products (Coley's toxins) on malignant tumours in man. Acta Med Scand 1953;274:29-97.
9. Woglem WH. A critique of tumour resistance. J Cancer Res 1923;7:283-311.
10. Denekamp J, Hill S. Angiogenic attack as a therapeutic strategy for cancer. Radiother Oncol 1991;Suppl. 20:103-12.
11. Denekamp J. The tumour microcirculation as a target in cancer therapy: a clearer perspective. Eur J Clin Invest 1999;29:733-6.
12. Kerbel RS, Kamen BA. The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004;4:423-36.
13. Garcia-Barros M, Paris F, Cordon-Cardo C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003;300:1155-9.
14. Wachsberger P, Burd R, Dicker AP. Tumor response to ionising radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms on interaction. Clin Cancer Res 2003;9:1957-71.
15. Siemann DW, Bibby MC, Dark GG, et al. Differentiation and definition of vascular-targeted therapies. Clin Cancer Res 2005;11:416-20.
16. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-76.
17. Pugh CW, Ratcliffe PJ. Regulation of angiogenesis by hypoxia: role of the HIF system. Nat Med 2003;9:677-84.
18. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-39.
19. Marmé D. The impact of anti-angiogenic agents on cancer therapy. J Cancer Res Clin Oncol 2003;129:607-20.
20. Eskens FA. Angiogenesis inhibitors in clinical development; where are we now and where are we going? Br J Cancer 2004;90:1-7.
21. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005;438:967-74.
22. National Cancer Institute Web site: http://www. cancer.gov/ clinicaltrials.
23. Horsman MR, Overgaard J. Thermal radiosensitization in animal tumors: the potential for therapeutic gain. In: Urano M, Douple E, editors. Hyperthermia and oncology, vol. 2. Utrecht: VSP: 1985. p.113-45.
24. Chaplin DJ, Dougherty GJ. Tumour vasculature as a target for cancer therapy. Br J Cancer 1999;80:57-64.
25. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004;10:415-27.
26. Siemann DW, Chaplin DJ, Horsman MR. Vascular targeting therapies for treatment of malignant disease. Cancer 2004;100:2491-9.
27. Baguley BC. Antivascular therapy of cancer: DMXAA. Lancet Oncol 2003;4:141-8.
28. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels. Nat Rev Cancer 2005;5:423-35.
29. Laird AD, Vajkoczy P, Shawver LK, et al. SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors. Cancer Res 2000;60:4152-60.
30. O'Reilly MS, Holmgren L, Chn C, Folkman J. Angiostatin induces and sustains dormancy of primary tumors in mice. Nat Med 1996;2:689-92.
31. Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signalling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002;62:4645-55.
32. Horsman MR, Murata R. Combination of vascular targeting agents with thermal or radiation therapy. Int J Radiat Oncol Biol Phys 2002;54:1518-23.
33. Landuyt W, Verdoes O, Darius DO, et al. Vascular targeting of solid tumours: a major "inverse" volume-response relationship following combretastatin A-4 phosphate treatment of rat rhabdomyosarcomas. Eur J Cancer 2000;36:1833-43.
34. Siemann DW. Vascular targeting agents. Horizons Cancer Ther 2002;3:4-15.
35. Siemann DW, Rojiani AM. The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumors. Int J Radiat Oncol Biol Phys 2005;62:846-53.
36. Shi W, Siemann DW. Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474. In Vivo 2005;19:1045-50.
37. Ching LM, Xu ZF, Gummer BH, Palmer BD, Joseph WR, Baguley BC. Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1995;72:339-43.
38. Ching LM, Browne WL, Tchernegovski R, Gregory T, Baguley BC, Palmer BD. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-α and enhancement of anti-tumour activity. Br J Cancer 1998;78:336-43.
39. Cao Z, Joseph WR, Browne WL, et al. Thalidomide increases both intra-tumoural tumour necrosis factor-α production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid. Br J Cancer 1999;80:716-23.
40. Mysliwski A, Bigda J, Koszalka P, Szmit E. Synergistic effect of the angiogenesis inhibitor TNP-470 and tumor necrosis factor (TNF) on Bomirski Ab melanoma in hamsters. Anticancer Res 2000;20:4643-7.
41. Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with either ionizing radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001;49:443-50.
42. Nordsmark N, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol l996;41:31-9.
43. Brizel DM, Dodge RK, Clough RW, Dewhirst MW. Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 1999;53:113-7.
44. Hoeckel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15.
45. Nordsmark N, Alsner J, Keller J, et al. Hypoxia in human soft tissue sarcomas: adverse impact on survival and no association with p53 mutations. Br J Cancer 2001;84:1070-5.
46. Lee C-G, Heijn M, di Tomaso E, et al. Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000;60:5565-70.
47. Gong H, Pöttgen C, Stüben G, Havers W, Stuschke M, Schweigerer L. Arginine deiminase and other anti-angiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. Int J Cancer 2003;106:723-8.
48. Drevs J, Müller-Driver R, Wittig C, et al. PTK787/ZK 222584, a specific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging. Cancer Res 2002;62:4015-22.
49. Schuuring J, Bussink J, Bernsen HJJA, Peeters W, van der Kogel AJ. Irradiation combined with SU5416: microvascular changes and growth delay in a human xenograft glioblastoma tumor line. Int J Radiat Oncol Biol Phys 2005;61:529-34.
50. Hansen-Algenstaedt N, Stoll BR, Padera TP, et al. Tumor oxygenation in hormone-dependent tumors during vascular endothelial growth factor receptor-2-blockade, hormone ablation, and chemotherapy. Cancer Res 2000;60:4556-60.
51. Shi W, Teschendorf C, Muzyczka N, Siemann DW. Gene therapy delivery of endostatin enhances the treatment efficacy of radiation. Radiother Oncol 2003;66:1-9.
52. Dings RPM, Williams BW, Song CW, Griffioen AW, Mayo KH, Griffin RJ. Anginex synergizes with radiation therapy to inhibit tumor growth by radiosensitizing endothelial cells. Int J Cancer 2005;115:312-9.
53. Lund EL, Bastholm L, Kristjansen PEG. Therapeutic synergy of TNP-470 and ionizing radiation: effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts. Clin Cancer Res 2000;6:971-8.
54. Hess C, Vuong V, Hegyi I, et al. Effect of VEGF receptor inhibitor PTK787/ZK222548 combined with ionizing radiation on endothelial cells and tumour growth. Br J Cancer 2001;85:2010-6.
55. Fenton BM, Paoni SF, Grimwood BG, Ding I. Disparate effects of endostatin on tumor vascular perfusion and hypoxia in two murine mammary carcinomas. Int J Radiat Oncol Biol Phys 2003;57:1038-46.
56. Bernsen HJJA, Rijken PFJW, Peters JPW, et al. Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status. J Neurooncol 1999;44:129-36.
57. Fenton BM, Paoni SF, Ding I. Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors. Cancer Res 2004;64:5712-9.
58. Leith JT, Papa G, Quaranto L, Michelson S. Modifications of the volumetric growth response and steady-state hypoxic fractions of xenografted DLD-2 human colon carcinomas by administration of basic fibroblast growth factor or suramin. Br J Cancer 1992;66:345-8.
59. Murata R, Nishimura Y, Hiraoka M. An anti-angiogenic agent (TNP-470) inhibited reoxygenation during fractionated radiotherapy of murine mammary carcinoma. Int J Radiat Oncol Biol Phys 1997;37:1107-13.
60. Griffin RJ, Williams BW, Wild R, Cherrington JM, Park H, Song CW. Simultaneous inhibition of the receptor kinase activity of vascular endothelial, fibroblast, and platelet-derived growth factors suppresses tumor growth and enhances tumor radiation response. Cancer Res 2002;62:1702-6.
61. Williams KJ, Telfer BA, Brave S, et al. ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 2004;10:8587-93.
62. Kozin SV, Boucher Y, Hicklin DJ, Bohlen P, Jain RK, Suit HD. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001;61:39-44.
63. Teicher BA, Holden SA, Ara G, et al. Influence of an anti-angiogenic treatment on 9L gliosarcoma: oxygenation and response to cytotoxic therapy. Int J Cancer 1995;61:732-7.
64. Rofstad EK, Henriksen K, Galappathi K, Mathiesen B. Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res 2003;63:4055-61.
65. Winkler F, Kozin SV, Tong R, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004;6:553-63.
66. Ansiaux R, Baudelet C, Jordan BF, et al. Thalidomide radiosensitizes tumors through early changes in the tumor microenvironment. Clin Cancer Res 2005;11:743-50.
67. Segers J, Di Fazio V, Ansiaux R, et al. Potentiation of cyclophosphamide chemotherapy using the anti-angiogenic drug thalidomide: importance of optimal scheduling to exploit the "normalization" window of the tumor vasculature. Cancer Lett 2006;244:129-35.
68. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7:987-9.
69. Boucher Y, Baxter LT, Jain RK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990;50:4478-84.
70. Milosevic M, Fyles A, Hedley D, Hill R. The human tumor microenvironment: invasive (needle) measurement of oxygen and interstitial fluid pressure. Semin Radiat Oncol 2004;14:249-58.
71. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004;64:3731-6.
72. Huber PE, Bischof M, Jenne J, et al. Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 2005;65:3643-55.
73. Teicher BA, Holden SA, Ara G, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994;57:920-5.
74. Kallinowski F, Moehle R, Vaupel P. Substantial enhancement of tumor hyperthermic response by tumor necrosis factor. In: Sugahara T, Saito M, editors. Hyperthermic oncology, vol. I. London: Taylor and Francis; 1989. p.258-9.
75. Lin JC, Park HJ, Song CW. Combined treatment of IL-α and TNF-α potentiates the antitumour effect of hyperthermia. Int J Hyperthermia 1996;12:335-44.
76. Hill SA, Sampson LE, Chaplin DJ. Anti-vascular approaches to solid tumour therapy: evaluation of vinblastine and flavone acetic acid. Int J Cancer 1995;63:119-23.
77. Chaplin DJ, Pettit GR, Parkins CS, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of tubulin binding agents. Br J Cancer 1996;74:S86-8.
78. 4AN rat gliomas: therapeutic implications of the vascular phenotype. Int J Radiat Oncol Biol Phys 2001;51:535-44.
79. Lew YS, Brown SL, Griffin RJ, Song CW, Kim JH. Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999;59:6033-7.
80. Griffin RJ, Lee SH, Rood KL, et al. Use of arsenic trioxide as an antivascular and thermosensitizing agent in solid tumors. Neoplasia 2000;2:555-60.
81. Horsman MR, Sampson LE, Chaplin DJ, Overgaard J. The in vivo interaction between flavone acetic acid and hyperthermia. Int J Hyperthermia 1996;12:779-89.
82. Bibby M, Double JA, Loadman PM, Duke CV. Reduction of tumor blood flow by flavone acetic acid: a possible component of therapy. J Natl Cancer Inst 1989;81:216-20.
83. Lash CJ, Li AE, Rutland M, Baguley BC, Zwi LJ, Wilson WR. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4- acetic acid (DMXAA) by the combination with 5-hydroxytryptamine and bioreductive drugs. Br J Cancer 1998;78:439-45.
84. Murata R, Overgaard J, Horsman MR. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues. Int J Radiat Biol 2001;77:195-204.
85. Siemann DW, Mercer E, Lepler S, Rojiani AM. Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy. Int J Cancer 2002;99:1-6.
86. Dark GD, Hill SA, Prise VE, Tozer GM, Pettit GR, Chaplin DJ. Combretastatin A-4, an agent that displays potent and selective toxicity towards tumor vasculature. Cancer Res 1997;57:1829-34.
87. Tozer GM, Prise VE, Wilson J, et al. Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues. Cancer Res 1999;59:1626-34.
88. Davis PD, Dougherty GJ, Blakey DC, et al. ZD6126: a novel vascular-targeting agent that causes selective destruction of tumor vasculature. Cancer Res 2002;62:7247-53.
89. Siemann DW, Rojiani AM. Enhancement of radiation therapy by the novel vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;53:164-71.
90. Horsman MR, Murata R. Vascular targeting effects of ZD6126 in a C3H mouse mammary carcinoma and the enhancement of radiation response. Int J Radiat Oncol Biol Phys 2003;57:1047-55.
91. Hori K, Saito S. Microvascular mechanisms by which the combretastatin A-4 derivative AC7770 (AVE8062) induces tumour blood flow stasis. Br J Cancer 2003;89:1334-44.
92. Hori K, Saito S, Sato Y, et al. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with antivascular drug and cytoloxic drugs: implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062). Eur J Cancer 2003;39:1957-66.
93. Hill SA, Tozer GM, Pettit GR, Chaplin DJ. Preclinical evaluation of the antitumour activity of the novel vascular targeting agent Oxi 4503. Anticancer Res 2002;22:1453-8.
94. Howell SE, Cooper PA, Thompson MJ, et al. Anti-tumor and anti-vascular effects of the novel tubulin-binding agent combretastatin A-I phosphate. Anticancer Res 2002;22:3933-40.
95. Hua J, Sheng Y, Pinney KG. Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate. Anticancer Res 2003;23:1433-40.
96. Sheng Y, Hua J, Pinney KG, et al. Combretastatin family member Oxi4503 induces tumor vascular collapse through the induction of endothelial apoptosis. Int J Cancer 2004;111:604-10.
97. Shi W, Siemann DW. Preclinical studies of the novel vascular disrupting agent MN-029. Anticancer Res 2005;25:3899-904.
98. Murata R, Siemann DW, Overgaard J, Horsman MR. Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumours. Radiother Oncol 2001;60:155-61.
99. Murata R, Overgaard J, Horsman MR. Potentiation of the anti-tumor effect of hyperthermia by combining with the vascular targeting agent 5,6-dimethylxanthenone-4-acetic acid. Int J Hyperthermia 2001;17:508-19.
100. Galbraith SM, Chaplin DJ, Lee F, et al. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo. Anticancer Res 2001;21:93-102.
101. Kanthou C, Tozer GM. The tumor vascular targeting agent combretastatin A-4 phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in human endothelial cells. Blood 2002;99:2060-9.
102. Blakey DC, Westwood FH, Walker M, et al. Antitumor activity of the novel vascular targeting agent ZD6126 in a panel of tumor models. Clin Cancer Res 2002;8:1974-83.
103. Ferrero E, Villa A, Ferrero ME, et al. Tumor necrosis factor α-induced vascular leakage involves PECAM1 phosphorylation. Cancer Res 1996;56:3211-5.
104. Tozer GM, Prise VE, Wilson J, et al. Mechanisms associated with tumor vascular shut-down induced by combretastatin A-4 phosphate: intravital microscopy and measurement of vascular permeability. Cancer Res 2001;61:6413-22.
105. Kim JH, Lew YS, Kolozsvary A, Ryu S, Brown SL. Arsenic trioxide enhances radiation response of 9L glioma in the rat brain. Radiat Res 2003;160:662-6.
106. Robinson SP, McIntyre DJO, Checkley D, et al. Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging. Br J Cancer 2003;88:1592-7.
107. Galbraith SM, Maxwell RJ, Lodge MA, et al. Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. J Clin Oncol 2003;21:2831-42.
108. Evelhoch JL, LoRusso PM, He Z, et al. Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126. Clin Cancer Res 2004;10:3650-7.
109. Zhao L, Ching L-M, Kestell P, Kelland LR, Baguley BC. Mechanisms of tumor vascular shutdown induced by 5,6-dimethylxanthenone-4-acetic acid (DMXAA): increased tumor vascular permeability. Int J Cancer 2005;116:322-6.
110. Ferretti S, Allegrini PR, O'Reilly T, et al. Patupilone induced vascular disruption in orthotopic rodent tumor models detected by magnetic resonance imaging and interstitial fluid pressure. Clin Cancer Res 2005;11:7773-84.
111. Skliarenko JV, Lunt SJ, Gordon ML, Vitkin A, Milosevic M, Hill RP. Effects of the vascular disrupting agent ZD6126 on interstitial fluid pressure and cell survival in tumours. Cancer Res 2006;66:2074-80.
112. 4An rat gliomas. Cancer Lett 2002;178:209-17.
113. Vincent L, Kermani P, Young LM, et al. Combretastatin A4 phosphate induces rapid regression of tumor neu vessels and growth through interference with vascular endothelial-cadherin signalling. J Clin Invest 2005;115:2992-3006.
114. Sun J-R, Brown JM. Enhancement of the antitumor effect of flavone acetic acid by the bioreductive cytotoxic drug SR 4233 in a murine carcinoma. Cancer Res 1989;49:5664-70.
115. Grosios K, Holwell SE, McGown AT, Pettie GR, Bibby MC. In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. Br J Cancer 1999;81:1318-27.
116. Chaplin DJ, Hill SA. The development of combretastatin A4 phosphate as a vascular targeting agent. Int J Radiat Oncol Biol Phys 2002;54:1491-6.
117. Moulder JE, Rockwell S. Hypoxic fractions in solid tumors. Int J Radiat Oncol Biol Phys 1984;10:695-712.
118. Horsman MR, Ehrnrooth E, Ladekarl M, Overgaard J. The effect of combretastatin A-4 disodium phosphate in a C3H mouse mammary carcinoma and a variety of murine spontaneous tumors. Int J Radiat Oncol Biol Phys 1998;42:895-8.
119. Wachsberger PR, Bird R, Marero N, et al. Effect of the tumor vascular-damaging agent, ZD6126, on the radioresponse of U87 glioblastoma. Clin Cancer Res 2005;11:835-42.
120. Eikesdal HP, Bjerkvig R, Raleigh JA, Mella O, Dahl O, Tumor vasculature is targeted by the combination of combretastatin A-4 and hyperthermia. Radiother Oncol 2001;61:313-20.
121. El-Emir E, Boxer GM, Petrie IA, et al. Tumour parameters affected by combretastatin A-4 phosphate therapy in a human colorectal xenograft model in nude mice. Eur J Cancer 2005;41:799-806.
122. Zhao D, Jiang L, Hahn EW, Mason RP. Tumor physiologic response to corebretastatin A4 phosphate assessed by MRI. Int J Radiat Oncol Biol Phys 2005;62:872-80.
123. Griffiths JH. Are cancer cells acidic? Br J Cancer 1991;64:425-7.
124. Sakaguchi Y, Maehara Y, Baba H, Kusumoto T, Sugimachi K, Newman RA. Flavone acetic acid increases the antitumor effect of hyperthermia in mice. Cancer Res 1992;52:3306-9.
125. Breidahl T, Nielsen FU, Stodkilde-Jorgensen H, Maxwell RJ, Horsman MR. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid, and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS. Acta Oncol 2006;45:306-16.
126. 1H MRI. Int J Radiat Oncol Biol Phys 1998;42:891-4.
127. Beauregard DA, Thelwall PE, Chaplin DJ, Hill SA, Adams GE, Brindle KM. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status. Br J Cancer 1998;77:1761-7.
128. Gorski DH, Mauceri HJ, Salloum RM, et al. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 1998;58:5686-9.
129. Gorski DH, Mauceri HJ, Salloum RM, Halpern A, Seetharam S, Weichselbaum RR. Prolonged treatment with angiostatin reduces metastatic burden during radiation therapy. Cancer Res 2003;63:308-11.
130. Griscelli F, Li H, Cheong C, et al. Combined effects of radiotherapy and angiostatin gene therapy in glioma tumor model. Proc Natl Acad Sci U S A 2000;97:6698-703.
131. Hanna NN, Seetharam S, Mauceri HJ, et al. Antitumor interaction of short-course endostatin and ionizing radiation. Cancer J 2000;6:287-93.
132. Gorski DH, Beckett MA, Jaskowiak NT, et al. Blockade of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999;59:3374-8.
133. Guptra VK, Jaskowiak NT, Beckett MA, et al. Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 2002;8:47-54.
134. Lu B, Geng L, Musiek A, et al. Broad spectrum receptor tyrosine kinase inhibitor, SU6668, sensitizes radiation via targeting survival pathway of vascular endothelium. Int J Radiat Oncol Biol Phys 2004;58:844-50.
135. Schueneman AA, Himmelfarb K, Geng L, et al. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res 2003;63:4009-16.
136. Zips D, Hessel F, Krause M, et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005;61:908-14.
137. Mauceri HJ, Hanna NN, Beckett MA, et al. Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 1998;394:287-91.
138. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;61:2413-9.
139. Ning S, Laird D, Cherrington JM, Knox SJ. The antiangiogenic agents SU5416 and SU6668 increase antitumor effects of fractionated irradiation. Radiat Res 2002;157:45-51.
140. Zips D, Krause M, Hessel F, et al. Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 2003;23:3869-76.
141. Brazelle WD, Shi W, Siemann DW. VEGF associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys 2006;65:836-41.
142. Damiano V, Melisi D, Bianco C, et al. Cooperative antitumor effect of multitargeted kinase inhibitor ZD6474 and ionizing radiation in glioblastoma. Clin Cancer Res 2005;11:5639-44.
143. Kaliski A, Maggiorella L, Cengel KA, et al. Angiogenesis and tumor growth inhibition by a matrix metalloproteinase inhibitor targeting radiation-induced invasion. Mol Cancer Ther 2005;4:1717-28.
144. Steel GG, Peckham MJ. Exploitable mechanisms in combined radiotherapy-chemotherapy: the concept of additivity. Int J Radiat Oncol Biol Phys 1979;5:85-91.
145. Steel GG. Terminology in the description of drug-radiation interactions. Int J Radiat Oncol Biol Phys 1979;5:1145-50.
146. Gray LH, Conger AD, Ebert M, et al. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in radiotherapy. Br J Radiol 1953;26:638-48.
147. Horsman MR, Overgaard J. The oxygen effect and tumour microenvironment. In: Steel GG, editor. Basic clinical radiobiology for radiation oncologists. 3rd ed. London: Edward Arnold; 2002. p. 158-68.
148. α) on the growth of mouse mammary carcinoma. Radiat Res 1955;2:180-91.
149. Hewitt HB, Blake ER. The growth of transplanted murine tumours in pre-irradiated sites. Br J Cancer 1968;22:808-24.
150. Zips D, Eicheler W, Geyer P, et al. Enhanced susceptibility of irradiated tumor vessels to vascular endothelial growth factor receptor tyrosine kinase inhibition. Cancer Res 2005;65:5374-9.
151. Abdollahi A, Lipson KE, Han X, et al. SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 2003;63:3755-63.
152. Li L, Rojiani A, Siemann DW. Targeting the tumor vasculature with combretastatin A-4 disodium phosphate: effects on radiation therapy. Int J Radiat Oncol Biol Phys 1998;42:899-903.
153. Chaplin DJ, Pettit GR, Hill SA. Anti-vascular approaches to solid tumour therapy: evaluation of combretastatin A4 phosphate. Anticancer Res 1999;19:189-96.
154. Wilson WW, Li AE, Cowan D, Siim BG. Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid. Int J Radiat Oncol Biol Phys 1998;42:905-8.
155. Murata R, Siemann DW, Overgaard J, Horsman MR. Improved tumor response by combining radiation and the vascular damaging drug 5,6-dimethylxanthenone-4- acetic acid. Radiat Res 2001;156:503-9.
156. Kimura K, Bowen C, Spiegel S, Gelmann EP. Tumor necrosis factor-α sensitizes prostate cancer cells to γ-irradiation-induced apoptosis. Cancer Res 1999;59:1606-14.
157. Ahmed B, Landuyt W, Griffioen AW, van Oosterom A, van den Bogaert W, Lambin P. In vivo antitumour effect of combretastatin A-4 phosphate added to fractionated radiation. Anticancer Res 2006;26:307-10.
158. Murata R, Overgaard J, Horsman MR. Combining combretastatin A-4 disodium phosphate and radiation in a fractionated schedule to improve local tumour control in mice. Radiother Oncol 2000;56:S98.
159. Horsman MR, Murata R, Overgaard J. Combination studies with combretastatin and radiation: effects in early and late responding tissues. Radiother Oncol 2002;64:550.
160. Browder T, Butterfield CE, Kraling BM, et al. Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 2000;60:1878-86.
161. Klement G, Huang P, Mayer B, et al. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin Cancer Res 2002;8:221-32.
162. Zhang L, Yu D, Hicklin DJ, Hannay JAF, Ellis LM, Pollock RE. Combined anti-fetal liver kinase 1 monoclonal antibody and continuous low-dose doxorubicin inhibits angiogenesis and growth of human soft tissue sarcoma xenografts by induction of endothelial cell apoptosis. Cancer Res 2002;62:2034-42.
163. Yap R, Veliceasa D, Emmenegger U, et al. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin Cancer Res 2005;11:6678-85.
164. Qian CN, Min HQ, Lin HL, Hong MH. Combination of angiogenesis inhibitor TNP-470 with cytotoxic drugs in experimental therapy of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol 2000;109:641-5.
165. Fujii T, Tachibana M, Dhar DK, et al. Combination therapy with paclitaxel and thalidomide inhibits angiogenesis and growth of human colon cancer xenograft in mice. Anticancer Res 2003;23:2405-12.
166. Zhang X, Galardi E, Duquette M, Lawler J, Parangi S. Antiangiogenic treatment with three thrombospondin-1 type 1 repeats versus gemcitabine in an orthotopic human pancreatic cancer model. Clin Cancer Res 2005;11:5622-30.
167. Inoue K, Chikazawa M, Fukata S, Yoshikawa C, Shuin T. Docetaxel enhances the therapeutic effect of the angiogenesis inhibitor TNP-470 (AGM-1470) in metastatic human transitional cell carcinoma. Clin Cancer Res 2003;9:886-99.
168. Song S, Wientjes MG, Walsh C, Au JL-S. Nontoxic doses of suramin enhance activity of paclitaxel against lung metastases. Cancer Res 2001;61:6145-50.
169. Song S, Yu B, Wei Y, Wientjes MG, Au JL-S. Low-dose suramin enhanced paclitaxel activity in chemotherapy-naive and paclitaxel-pretreated human breast xenograft tumors. Clin Cancer Res 2004;10:6058-65.
170. Zhang Y, Song S, Yang F, Au JL-S, Wientjes MG. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors. J Pharmacol Exp Ther 2001;299:426-33.
171. Xin Y, Lyness G, Chen D, Song S, Wientjes MG, Au JL-S. Low dose suramin as a chemosensitizer of bladder cancer to mitomycin C. J Urol 2005;174:322-7.
172. Wu Y, Yang L, Hu B, et al. Synergistic anti-tumor effect of recombinant human endostatin adenovirus combined with gemcitabine. Anticancer Drugs 2005;16:551-7.
173. Heere-Ress E, Boehm J, Thallinger C, et al. Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplatation model. J Invest Dermatol 2005;125:201-6.
174. Inoue K, Slaton JW, Davis DW, et al. Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the
175. Hu L, Hofmann J, Zaloudek C, Ferrara N, Hamilton T, Jaffe RB. Vascular endothelial growth factor immunoneutralization plus paclitaxel markedly reduces tumor burden and ascites in athymic mouse model of ovarian cancer. Am J Pathol 2002;161:1917-24.
176. Wild R, Dings RPM, Subramanian I, Ramakrishnan S. Carboplatin selectively induces the VEGF stress response in endothelial cells: potentiation of antitumor activity by combination treatment with antibody to VEGF. Int J Cancer 2004;110:343-51.
177. Bocci G, Danesi R, Marangoni G, et al. Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine. Eur J Pharmacol 2004;498:9-18.
178. Jia L, Zhang M-H, Yuan S-Z, Huang W-G. Anti-angiogenic therapy for human pancreatic carcinoma xenografts in nude mice. World J Gastroenterol 2005;11:447-50.
179. Fox WD, Higgins B, Maiese KM, et al. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer. Clin Cancer Res 2002;8:3226-31.
180. Börgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999;19:4203-14.
181. Devineni D, Klein-Szanto A, Gallo JM. Uptake of temozolomide in a rat glioma model in the presence and absence of the angiogenesis inhibitor TNP-470. Cancer Res 1996;56:1983-7.
182. Ma J, Pulfer S, Li S, Chu J, Reed K, Gallo JM. Pharmacodynamic-mediated reduction of temozolomide tumor concentrations by the angiogenesis inhibitor TNP-470. Cancer Res 2001;61:5491-8.
183. Teicher BA, Lazo JS, Sartorelli AC. Classification of antineoplastic agents by their selective toxicities toward oxygenated and hypoxic tumor cells. Cancer Res 1981;41:73-81.
184. Tannock I, Guttman P. Response of Chinese hamster ovary cells to anti-cancer drugs under aerobic and hypoxic conditions. Br J Cancer 1981;43:245-8.
185. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother Oncol 1984;2:343-66.
186. Grau C, Overgaard J. Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother Oncol 1988;13:301-9.
187. Durand RE. The influence of microenvironmental factors on the activity of radiation and drugs. Int J Radiat Oncol Biol Phys 1991;20:253-8.
188. Grau C, Overgaard J. Effect of etoposide, carmustine, vincristine, 5-fluorouracil, or methotrexate on radiobiologically oxic and hypoxic cells in a C3H mouse mammary carcinoma. Cancer Chemother Pharmacol 1992;30:277-80.
189. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-42.
190. Edwards HS, Bremner JCM, Stratford IJ. Induction of tumour hypoxia by FAA and TNF: interaction with bioreductive drugs. Int J Radiat Biol 1991;60:373-7.
191. Parkins CS, Denekamp J, Chaplin DJ. Enhancement of mitomycin-C cytotoxicity by combination with flavone acetic acid in a marine tumour. Anticancer Res 1993;13:1437-42.
192. Cliffe S, Taylor ML, Rutland M, Baguley BC, Hill RP, Wilson WR. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int J Radiat Oncol Biol Phys 1994;29:373-7.
193. Wilson WR, Denny WA, Pullen SM, et al. Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide, and AQ4N. Br J Cancer 1996;74:S43-7.
194. Parkins CS, Chadwick JA, Chaplin DJ. Enhancement of chlorambucil cytotoxicity by combination with flavone acetic acid in a murine tumour. Anticancer Res 1994;14:1603-8.
195. Pruijn FB, van Daalen M, Holford NHG, Wilson WR. Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid. Cancer Chemother Pharmacol 1997;39:541-6.
196. Li L, Rojiani AM, Siemann DW. Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcoma. Acta Oncol 2002;41:91-7.
197. Grosios K, Loadman PM, Swaine DJ, Pettit GR, Bibby MC. Combination chemotherapy with combretastatin A-4 phosphate and 5-fluorouracil in an experimental murine colon adenocarcinoma. Anticancer Res 2000;20:229-34.
198. Siemann DW, Rojiani AM. Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126. Int J Radiat Oncol Biol Phys 2002;54:1512-7.
199. Morinaga Y, Suga Y, Ehara S, Harada K, Nihei Y, Suzuki M. Combination effect of AC-7700, a novel combretastatin A-4 derivative, and cisplatin against murine and human tumors in vivo. Cancer Sci 2003;94:200-4.
200. Jain RK, Grantham FH, Gullino PM. Blood flow and heat transfer in Walker 256 mammary carcinoma. J Natl Cancer Inst 1979;62:927-33,
201. Patterson J, Strang R. The role of blood flow in hyperthermia. Int J Radiat Oncol Biol Phys 1979;5:235-41.
202. Overgaard J, Bichel P. The influence of hypoxia and acidity on the hyperthermic response of malignant cells in vitro. Radiology 1977;123:511-4.
203. Gerweck LE, Nygaard TG, Burlett M. Response of cells to hyperthermia under acute and chronic hypoxic conditions. Cancer Res 1979;39:966-72.
204. Thrall DE, Gillette EL, Dewey WC. Effect of heat and ionizing radiation on normal and neoplastic tissue of the C3H mouse. Radiat Res 1975;63:363-77.
205. Hill SA, Denekamp J. The effect of vascular occlusion on the thermal sensitization of a mouse tumor. Br J Radiol 1978;51:997-1002.
206. Horsman MR, Christensen KL, Overgaard J. Hydralazine-induced enhancement of hyperthermic damage in a C3H mammary carcinoma in vivo. Int J Hyperthermia 1989;5:123-36.
207. Prescott DM, Samulski TV, Dewhirst MW, et al. Use of nitroprusside to increase tissue temperature during local hyperthermia in normal and tumor-bearing dogs. Int J Radiat Oncol Biol Phys 1992;23:377-85.
208. Urano M, Montoya V, Booth A. Effect of hyperglycemia on the thermal response of murine normal and tumor tissue. Cancer Res 1983;43:453-5.
209. 4An rat glioma: lack of interaction with the angiogenesis inhibitor batimastat. Int J Hyperthermia 2002;18:141-52.
210. Yano T, Tanase M, Watanabe A, et al. Enhancement effect of an anti-angiogenic agent, TNP-470, on hyperthermia-induced growth suppression of human esophageal and gastric cancers transplantable to nude mice. Anticancer Res 1995;15:1355-8.
211. Nishimura Y, Murata R, Hiraoka M. Combined effects of an angiogenesis inhibitor (TNP-470) and hyperthermia. Br J Cancer 1996;73:270-4.
212. Griffin RJ, Monzen H, Williams BW, Park H, Lee SH, Song CW. Arsenic trioxide induces selective tumour vascular damage via oxidative stress and increases thermosensitivity of tumours. Int J Hyperthermia 2003;19:575-89.
213. Horsman MR, Murata R, Overgaard J. Improving local tumor control by combining vascular targeting drugs, mild hyperthermia, and radiation. Acta Oncol 2001;40:497-503.
214. 4An rat glioma. Int J Radiat Oncol Biol Phys 2000;46:645-52.
215. Murata R, Overgaard J, Horsman MR. Combretastatin A-4 disodium phosphate: a vascular targeting agent that improves the anti-tumor effects of hyperthermia, radiation, and mild thermoradiotherapy. Int J Radiat Oncol Biol Phys 2001;51:1018-24.
216. Overgaard J. Rationale and problems in the design of clinical trials. In Overgaard J, editor. Hyperthermic oncology vol. 2. London; Taylor and Francis: 1985. p.325-38.
217. Horsman MR, Overgaard J. Overcoming tumour radioresistance resulting from hypoxia. In: Steel GG, editor. Basic clinical radiobiology for radiation oncologists. 3rd ed. London: Edward Arnold; 2002. p.169-81.
218. Murata R, Horsman MJR. Tumour-specific enhancement of thermoradiotherapy at mild temperatures by the vascular targeting agent 5,6-dimethylxanthenone-4- acetic acid. Int J Hyperthermia 2004;20:393-404.
219. Henderson BW, Miller AC. Effects of scavengers of reactive oxygen and radical species on cell survival following photodynamic treatment in vitro: comparison to ionizing radiation. Radiat Res 1986;108:196-205.
220. Dimitroff CJ, Klohs W, Sharma A, et al. Anti-angiogenic activity of selected receptor tyrosine kinase inhibitors, PD1666285 and PD173074: implications for combination treatment with photodynamic therapy. Invest New Drugs 1999;17:121-5.
221. Zhou Q, Olivo M, Lye KYK, Moore S, Sharma A, Chowbay B. Enhancing the therapeutic responsiveness of photodynamic therapy with the antiangiogenic agents SU5416 and SU6668 in murine nasopharyngeal carcinoma models. Cancer Chemother Pharmacol 2005;56:569-77.
222. Pedley RB, Boden JA, Boden R, et al. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents. Cancer Res 1996;56:3293-300.
223. Pedley RB, Hill SA, Boxer GM, et al. Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin A-4 3-O-phosphate. Cancer Res 2001;61:4716-22.
224. Pedley RB, Sharma SK, Boxer GM, et al. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent. Cancer Res 1999;59:3998-4003.
225. Ahn G-O, Brown JM. Vasculature-disrupting strategies combined with bacterial spores targeting hypoxic regions of solid tumors. In: Siemann DW, editor. Vascular-targeted therapies in oncology. Chichester: John Wiley & Sons, Ltd.; 2006. p.261-76.
226. Sersa G, Willingham V, Milas L. Anti-tumor effects of tumor necrosis factor alone or combined with radiotherapy. Int J Cancer 1988;42:129-34.
227. Nishiguchi I, Willingham V, Milas L. Tumor necrosis factor as an adjunct to fractionated radiotherapy in the treatment of murine tumors. Int J Radiat Oncol Biol Phys 1990;18:555-8.
228. Mauceri HJ, Hanna NN, Wayne JD, Hallahan DE, Hellman S, Weichselbaum RR. Tumor necrosis factor α (TNF-α) gene therapy targeted by ionizing radiation selectively damages tumor vasculature. Cancer Res 1996;56:4311-4.
229. 3). FEBS Lett 2002;519:195-200.
230. Lew YS, Kolozsvary A, Brown SL, Kim JH. Synergistic interaction with arsenic trioxide and fractionated radiation in locally advanced murine tumor. Cancer Res 2002;62:4202-5.
231. Landuyt W, Ahmed B, Nuyts S, et al. In vivo antitumor effect of vascular targeting combined with ionising radiation or anti-angiogenesis treatment. Int J Radiat Oncol Biol Phys 2001;49:443-50.
232. Raben D, Bianco C, Damiano V, et al. Antitumor activity of ZD6126, a novel vascular-targeting agent, is enhanced when combined with ZD1839, an epidermal growth factor receptor tyrosine kinase inhibitor, and potentiates the effects of radiation in a human non-small cell lung cancer xcnograft model. Mol Cancer Ther 2004;3:977-83.
233. Shi W, Horsman MR, Siemann DW. Combined modality approaches using vasculature-disrupting agents. In: Siemann DW, editor. Vascular-targeted therapies in oncology. Chichester: John Wiley & Sons, Ltd.; 2006. p.123-36.
234. Teicher BA, Holden SA, Dupuis NP, et al. Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma. Breast Cancer Res Treat 1995;36:227-36.
235. Kato T, Sato K, Kakinuma H, Matsuda Y. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl) fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54:5143-7.
236. Morishita T, Mii Y, Miyauchi Y, et al. Efficacy of CDDP and AGM-1470 chemotherapy against lung metastasis in rat osteosarcoma depends on the timing of combined administration. Jpn J Clin Oncol 1997;27:236-9.
237. Shishido T, Yasoshima T, Denno K, Muyaiya M, Sato N, Hirata K. Inhibition of liver metastasis of pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn J Cancer Res 1998;89:963-9.
238. Morishita T, Miyauchi Y, Mii Y, et al. Delay in administration of CDDP until completion of AGM-1740 treatment enhances antimetastatic and antitumor effects. Clin Exp Metastasis 1999;17:15-8.
239. Teicher BA, Holden SA, Ara G, Korbut T, Menon K. Comparison of several antiangiogenic regimens alone and with cytotoxic therapies in the Lewis lung carcinoma. Cancer Chemother Pharmacol 1996;38:169-77.
240. Kakeji Y, Teicher BA. Preclinical studies of the combination of angiogenic inhibitors with cytotoxic agents. Invest New Drugs 1997;15:39-48.
241. Ma G, Masuzawa M, Hamada Y, et al. Treatment of murine angiosarcoma with etoposide, TNP-70, and prednisolone. J Dermatol Sci 2000;24:126-33.
242. Muramaki M, Miyake H, Hara J, Kawabata G, Kamidono S. Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and gemcitabine in a human bladder cancer KOTCC-1 model. J Urol 2004;172:1485-9.
243. Osswald H, Youssef M. Suramin enhancement of the chemotherapeutic actions of cyclophosphamide or adriamycin of intramuscularly-implanted Ehrlich carcinoma. Cancer Lett 1979;6:337-43.
244. Kikuchi Y, Hirata J, Hisano A, Tode T, Kita T, Nagata I. Complete inhibition of human ovarian cancer xenografts in nude mice by suramin and cis-diammine-dichloroplatinum(II). Gynecol Oncol 1995;58:11-5.
245. Mauceri MJ, Seetharam S, Bechett MA, et al. Angiostatin potentiates cyclophosphamide treatment of metastatic disease. Cancer Chemother Pharmacol 2002;50:412-8.
246. te Velde EA, Vogten JM, Gebbink MFGB, van Gorp JM, Voest EE, Borel Rinkes IHM. Enhanced antitumour efficacy by combining conventional chemotherapy with angiostatin or endostatin in a liver metastasis model. Br J Surg 2002;89:1302-9.
247. Bertolini I, Fusetti L, Mancuso P, et al. Endostatin, an antiangiogenic drug, induces tumor stabilisation after chemotherapy or anti-CD20 therapy in a NOD/SCID mouse model of human high-grade non-Hodgkin lymphoma. Blood 2000;96:282-7.
248. Abraham D, Abri S, Hofmann M, Höltl W, Aharinejad S. Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. J Urol 2003;170:1388-93.
249. Subramanian IV, Nguyen TMB, Truskinovsky AM, Tolar J, Blazar BR, Kamakrishnan S. Adeno-assoeiated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res 2006;66:4319-28.
250. Ding Q, Kestell P, Baguley BC, et al. Potentiation of the antitumour effect of cyclophosphamide in mice by thalidomide. Cancer Chemother Pharmaeol 2002;50:186-92.
251. Dings RPM, Yokoyama Y, Ramakrishnan S, Griffioen AW, Mayo KH. The designed angiostatic peptide anginex synergistically improves chemotherapy and antiangiogenesis therapy with angiostatin. Cancer Res 2003;63:382-5.
252. Allegrini G, Goulette FA, Darnowski JW, Calabresi P. Thrombospondin-1 plus irinotecan: a novel anti-angiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol 2004;53:261-6.
253. Soffer SZ, Moore JT, Kim E, et al. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. J Pediatr Surg 2001;36:1177-81.
254. Wildiers H, Guelens G, De Boeck G, et al. Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11. Br J Cancer 2003;88:1979-86.
255. Garofolo A, Naumova E, Manenti L, et al. The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically. Clin Cancer Res 2003;9:3476-85.
256. D'Alessandro N, Borsellino N. In vivo effects of tumor necrosis factor-α or flavone acetic acid in combination with doxorubicin on multidrug-resistant B16 melanoma. Anticancer Drugs 1996;7:281-7.
257. Siim BG, Lee AE, Shalal-Zwain S, Pruijn FB, McKeage MJ, Wilson WR. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Cancer Chemother Pharmacol 2003;51:43-52.
258. Horsman MR, Murata R, Breidahl T, et al. Combretastatins novel vascular targeting drugs for improving anti-cancer therapy. Adv Exp Med Biol 2000;476:311-23.
259. Wildiers H, Ahmed B, Guetens G, et al. Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence. Eur J Cancer 2004;40:284-90.
260. Goto H, Yano S, Matsumori Y, Ogawa H, Blakey DC, Sone S. Sensitization of tumor-associated endothelial cell apoptosis by the novel vascular-targeting agent ZD6126 in combination with cisplatin. Clin Cancer Res 2004;10:7671-6.
261. Shnyder SD, Cooper PA, Pettit GR, Lippert JW III, Bibby MC. Combretastatin A-1 phosphate potentiates the antitumour activity of cisplatin in a murine adenocarcinoma model. Anticancer Res 2003;23:1619-24.